Fiche centre
Intermountain Healthcare
Salt Lake City — United States
Essais liés4clinical trials
VilleSalt Lake Citylocalisation
PaysUnited Stateslocalisation
SourcelocaleCSV/MySQL
Informations
centreSynchronisé depuis ClinicalTrials.gov — NCT05819359
Essais cliniques associés
4| Molécule | Indication / population | Phase | NCT | Titre | Statut |
|---|---|---|---|---|---|
| BIA 28-6156 10 mg | Parkinson | Phase 2 | NCT05819359 | ACTIVATE — Efficacy, Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics of BIA 28-6156 in GBA-PD | COMPLETED |
| rondecabtagene autoleucel | SEP | Phase 3 | NCT07188558 | PiNACLE-H2H — A Study to Investigate Ronde-cel Versus Investigator's Choice CD19 CAR T-Cell Therapy | RECRUITING |
| BIA 28-6156 | Parkinson | À vérifier | NCT07522606 | Compassionate Use for BIA 28-6156 in Patients With Parkinson's Disease (PD) Who Have a Pathogenic Variant in the GBA1 Gene (GBA-PD) and Completed the ACTIVATE Study | NO_LONGER_AVAILABLE |
| Anti-hypertensive therapy | Hypertension | Phase 4 | NCT02299414 | Chronic Hypertension and Pregnancy (CHAP) Project | COMPLETED |